Call for Abstracts

Abstract submission is closed
Important Information
  • EXTENDED submission deadline: February 3rd, 2023
  • Notification of acceptance: February 24th, 2023
  • Registration: Presenters must be registered and have paid their registration fee by March 1st, 2023; otherwise, their abstract will be removed from the program.
  • It is the submitter’s responsibility to ensure that all co-authors approve of the abstract’s submission, publication, and potential presentation.
4th Summit on Stem Cell Derived Beta Cell Abstract Topics
  • Biomanufacturing
  • Clinical Trials
  • Encapsulation
  • Ethics
  • Genome editing
  • Islet Development
  • Off-target cells/safety considerations
  • Stem cell-derived islets
Abstract Submission Process
Choosing a Topic Category
During the submission process, you will be asked to select one topic category for your abstract. The topic category is the general theme under which the abstract will be reviewed and later assigned and published in the Congress materials (if accepted).
Abstract Structure

Abstracts must be comprised of four distinct sections:

  • Introduction: Describes previous research and the rationale for the current study
  • Method: Describes how the study was conducted
  • Results: Describes the results of the study
  • Conclusion: Summarize the study and discusses its implications

Please do not insert tables into the body of the abstracts. They will need to be uploaded into jpg, png or gif as a figure.

Abstract Guidelines

All abstracts must be submitted electronically through the Summit management system.

  • Abstracts should be submitted only in English.
  • There is no fee for submission.
  • The abstract text body is limited to 3,000 characters including spaces (about 400 words or more, depending on spacing). A maximum of two figures (in JPG, GIF or PNG with ideally 600 dpi) can be included. These will not count toward the word limit, nor will the information about authors, institutions and study groups. File size of 2 MB maximum for each figure. Make sure you submit your figure with no surrounding white space and the text is readable.
  • It is the submitter’s responsibility to ensure that all co-authors approve of the abstract submission, publication, and potential presentation.
  • Presenters from employers of commercial interests, selected for an oral or a poster presentation, may be required to submit additional information, including the presentation slides. Presenting content featuring clinical recommendations aligned to the business interests and/or products of the employer is strictly prohibited.
Policies for Abstract Submission
Copyright Policy
Abstracts should not include libelous or defamatory content. Material presented in abstracts should not violate any copyright laws. If figures/graphics/images have been taken from sources not copyrighted by the author, it is the author’s sole responsibility to secure the rights from the copyright holder in writing to reproduce those figures/graphics/images for both worldwide print and web publication. All reproduction costs charged by the copyright holder must be borne by the author.
Resubmission Policy
The Summit welcomes the submission of abstracts previously presented at national, regional or international meetings in the two years preceding the congress. Encores must be documented as such at the time of submission. To be accepted, the abstract must include significant additional data from the previous presentation/s. Submission will not be permitted if a manuscript has been published.
The Summit regards plagiarism as serious professional misconduct. All abstracts are screened for plagiarism and when identified, the abstract and any other abstracts submitted by the same author will be rejected. In addition, the submitting author’s profile and award application, in the case one has been submitted, will also be cancelled.
Organ Trafficking and Tourism Ethics Compliance

To be eligible to submit an abstract, you must disclose that the author(s)/ scientist(s) have not violated any aspect of the following Ethics Statement:

  • Declaration of Istanbul (DOI) ethics' statement 
  • Research conforms with the ethical statement on human research subject, Helsinki Declaration of The World Medical Association
  • The Ethics of Xenotransplantation (Xenotransplantation 10:194-203, 2003) For research involving human subjects - The Helsinki. 
  • The Transplantation Society Ethics statement 
Abstract Review and Selection Process
Abstract Review
  • All submitted abstracts will go through blind peer-review carried out by an international committee
  • All abstracts will be reviewed by at least three international referees selected by the Scientific Program Committee
  • Abstracts which do not meet the focus of the topic selected by the authors will be reassigned at the discretion of the Review Committee
  • Abstracts will be assessed based the following criteria:
    • Interest: Is the content original/important/relevant to our field?
    • Novelty: How and to what extent are the findings likely to influence clinical or research practice, education or policy?
    • Robustness and quality of the data: Are the methods/ methodological approach clearly described?  How confident is the reviewer in the strength/trustworthiness of the data and/or conclusions/discussion presented?
    • Presentation and Clarity: The basic purpose of the research/project is clear
Format of Presentation
Abstracts may be submitted for oral presentation (to be determined at the Committee’s discretion). Please note that space is very limited for oral abstract presentations.
Notification of Acceptance

Notification of acceptance or rejection will be sent to the submitting (corresponding) author by February 24th, 2023. Please note that only the corresponding author will receive the communication concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.

Organized by